Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas

Fig. 1

GBM stem cells express Sema3A ligand and receptors. Immunocytochemistry demonstrating expression of stem cell markers CD133 (a) and Nestin (b) (scale bar = 50 μm). Phase-contrast microscopy of a tumorsphere (scale bar = 200 μm) (c). Differentiation of xenografts results in loss of CD133 (d), as shown by immunostaining (scale bar = 50 μm). PCR demonstrating expression of Nrp1, PlxnA1, and Sema3A in BTSCs (uncropped gels presented in Supp Fig. 8) (e). Immunostaining showing Nrp1 is expressed in BTSCs (f) but not differentiated (DDX) cells (g) (scale bar = 100 μm). Elevated Nrp1 expression is associated with CD133-positive BTSCs by flow cytometric analysis of CD133 sorted BTSCs demonstrating 10-fold higher CD133 expression in CD133-high (green) cells compared to CD133-low (blue) (h). 95% of CD133-high fraction cells are positive for CD133, compared to only 47% of CD133-low cells, which have low expression levels (i). qRT-PCR analysis of Nrp1 and PlxnA1 expression in CD133-high and low fractions demonstrating a significant increase in Nrp1 mRNA expression in CD133-high cells compared to CD133-low, but no change in PlxnA1 expression (n = 6; p < 0.05) (j)

Back to article page